Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.
Samuel A GoldlustLouis Burt NaborsSigmund HsuNimish MohilePaul J DuicTara BenkersSamuel SingerMayank RaoLori CappelloSandra L SilbermanGeorge FarmerPublished in: Neuro-oncology advances (2024)
TPI 287 can be safely combined with BEV for the treatment of rGBM and preliminary efficacy supports further investigation of this combination.
Keyphrases